Search Results

There are 7713 results for: content related to: Analysis of CD4 + CD8 + double-positive T cells in blood, cerebrospinal fluid and multiple sclerosis lesions

  1. You have free access to this content
    Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis

    European Journal of Immunology

    Volume 42, Issue 3, March 2012, Pages: 790–798, Raquel Planas, Ilijas Jelc̆ić, Sven Schippling, Roland Martin and Mireia Sospedra

    Version of Record online : 27 DEC 2011, DOI: 10.1002/eji.201142108

  2. You have full text access to this OnlineOpen article
    Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

    Annals of Neurology

    Volume 76, Issue 6, December 2014, Pages: 802–812, Tatiana Plavina, Meena Subramanyam, Gary Bloomgren, Sandra Richman, Amy Pace, Sophia Lee, Brian Schlain, Denise Campagnolo, Shibeshih Belachew and Barry Ticho

    Version of Record online : 24 OCT 2014, DOI: 10.1002/ana.24286

  3. Natalizumab for induction of remission in Crohn's disease

    Intervention Review

    The Cochrane Library

    John K MacDonald and John WD McDonald

    Published Online : 24 JAN 2007, DOI: 10.1002/14651858.CD006097.pub2

  4. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy

    Annals of Neurology

    Volume 76, Issue 6, December 2014, Pages: 792–801, Clemens Warnke, Gloria von Geldern, Philipp Markwerth, Thomas Dehmel, Robert Hoepner, Ralf Gold, Michael Pawlita, Tania Kümpfel, Mathias Mäurer, Martin Stangel, Florian Wegner, Reinhard Hohlfeld, Vera Straeten, Volker Limmroth, Thomas Weber, Derik Hermsen, Christoph Kleinschnitz, Hans-Peter Hartung, Mike P. Wattjes, Anders Svenningson, Eugene Major, Tomas Olsson, Bernd C. Kieseier and Ortwin Adams

    Version of Record online : 8 MAY 2014, DOI: 10.1002/ana.24153

  5. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years

    European Journal of Neurology

    Volume 23, Issue 6, June 2016, Pages: 1101–1109, R. Zivadinov, D. Hojnacki, N. Bergsland, C. Kennedy, J. Hagemeier, R. Melia, D. P. Ramasamy, J. Durfee, E. Carl, M. G. Dwyer and B. Weinstock-Guttman

    Version of Record online : 21 MAR 2016, DOI: 10.1111/ene.12992

  6. You have free access to this content
    Monoclonal antibodies in treatment of multiple sclerosis

    Clinical & Experimental Immunology

    Volume 175, Issue 3, March 2014, Pages: 373–384, P. S. Rommer, A. Dudesek, O. Stüve and U.K. Zettl

    Version of Record online : 4 FEB 2014, DOI: 10.1111/cei.12197

  7. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

    Annals of Neurology

    Volume 68, Issue 3, September 2010, Pages: 304–310, Richard A. Rudick, Paul W. O'Connor, Chris H. Polman, Andrew D. Goodman, Soma S. Ray, Nancy M. Griffith, Stephanie A. Jurgensen, Leonid Gorelik, Fiona Forrestal, Alfred W. Sandrock and Susan E. Goelz

    Version of Record online : 24 AUG 2010, DOI: 10.1002/ana.22107

  8. You have full text access to this OnlineOpen article
    Comparative efficacy of switching to natalizumab in active multiple sclerosis

    Annals of Clinical and Translational Neurology

    Volume 2, Issue 4, April 2015, Pages: 373–387, Timothy Spelman, Tomas Kalincik, Annie Zhang, Fabio Pellegrini, Heinz Wiendl, Ludwig Kappos, Larisa Tsvetkova, Shibeshih Belachew, Robert Hyde, Freek Verheul, Francois Grand-Maison, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Alessandra Lugaresi, Jeannette Lechner-Scott, Celia Oreja-Guevara, Raymond Hupperts, Thor Petersen, Michael Barnett, Maria Trojano, Helmut Butzkueven and on behalf of the MSBase Investigators and the TOP investigators

    Version of Record online : 27 FEB 2015, DOI: 10.1002/acn3.180

  9. You have free access to this content
    Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients

    European Journal of Neurology

    Volume 23, Issue 1, January 2016, Pages: 182–189, M. I. Domínguez-Mozo, M. García-Montojo, A. Arias-Leal, Á. García-Martínez, J. L. Santiago, I. Casanova, V. Galán, R. Arroyo, M. Fernández-Arquero and R. Alvarez-Lafuente

    Version of Record online : 25 OCT 2015, DOI: 10.1111/ene.12834

  10. You have free access to this content
    Molecular targeted therapy against the blood–brain barrier in multiple sclerosis

    Clinical and Experimental Neuroimmunology

    Volume 5, Issue s1, December 2014, Pages: 28–34, Takashi Kanda

    Version of Record online : 18 DEC 2014, DOI: 10.1111/cen3.12167

  11. JC virus granule cell neuronopathy and GCN–IRIS under natalizumab treatment

    Annals of Neurology

    Volume 74, Issue 4, October 2013, Pages: 622–626, Sven Schippling, Christian Kempf, Fabian Büchele, Ivan Jelcic, Oliver Bozinov, Adriano Bont, Michael Linnebank, Mireia Sospedra, Michael Weller, Herbert Budka and Roland Martin

    Version of Record online : 16 SEP 2013, DOI: 10.1002/ana.23973

  12. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis

    Annals of Neurology

    Volume 75, Issue 6, June 2014, Pages: 925–934, Spyridon Chalkias, Xin Dang, Evelyn Bord, Marion C. Stein, R. Philip Kinkel, Jacob A. Sloane, Maureen Donnelly, Carolina Ionete, Maria K. Houtchens, Guy J. Buckle, Stephanie Batson and Igor J. Koralnik

    Version of Record online : 10 JUN 2014, DOI: 10.1002/ana.24148

  13. You have free access to this content
    Requirement for safety monitoring for approved multiple sclerosis therapies: an overview

    Clinical & Experimental Immunology

    Volume 175, Issue 3, March 2014, Pages: 397–407, P. S. Rommer, U. K. Zettl, B. Kieseier, H.-P. Hartung, T. Menge, E. Frohman, B. M. Greenberg, B. Hemmer and O. Stüve

    Version of Record online : 4 FEB 2014, DOI: 10.1111/cei.12206

  14. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab

    Inflammatory Bowel Diseases

    Volume 13, Issue 1, January 2007, Pages: 2–11, Bruce E. Sands, Richard Kozarek, Jack Spainhour, Charles F. Barish, Scott Becker, Lawrence Goldberg, Seymour Katz, Ronald Goldblum, Rena Harrigan, Deborah Hilton and Stephen B. Hanauer

    Version of Record online : 19 DEC 2006, DOI: 10.1002/ibd.20014

  15. Novel Immunomodulatory Approaches for the Management of Multiple Sclerosis

    Clinical Pharmacology & Therapeutics

    Volume 95, Issue 1, January 2014, Pages: 32–44, OH Kantarci, I Pirko and M Rodriguez

    Version of Record online : 19 DEC 2013, DOI: 10.1038/clpt.2013.196

  16. You have free access to this content
    Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (Tysabri®) in Inflammatory Diseases

    CNS Drug Reviews

    Volume 13, Issue 1, March 2007, Pages: 79–95, Olaf Stüve and Jeffrey L. Bennett

    Version of Record online : 24 APR 2007, DOI: 10.1111/j.1527-3458.2007.00003.x

  17. Natalizumab for relapsing remitting multiple sclerosis

    Intervention Review

    The Cochrane Library

    Eugenio Pucci, Giorgio Giuliani, Alessandra Solari, Silvana Simi, Silvia Minozzi, Carlo Di Pietrantonj and Ian Galea

    Published Online : 5 OCT 2011, DOI: 10.1002/14651858.CD007621.pub2

  18. What to expect after natalizumab cessation in a real-life setting

    Acta Neurologica Scandinavica

    Volume 130, Issue 2, August 2014, Pages: 97–102, S. Salhofer-Polanyi, A. Baumgartner, J. Kraus, E. Maida, M. Schmied and F. Leutmezer, The Austrian Tysabri Registry Group

    Version of Record online : 10 APR 2014, DOI: 10.1111/ane.12250

  19. Natalizumab for moderate to severe Crohn's disease in clinical practice: The Mayo Clinic Rochester experience

    Inflammatory Bowel Diseases

    Volume 18, Issue 12, December 2012, Pages: 2203–2208, S.V. Kane, S. Horst, W.J. Sandborn, B. Becker, B. Neis, M. Moscandrew, K.A. Hanson, W.J. Tremaine, D.H. Bruining, W.A. Faubion, D.S. Pardi, W.S. Harmsen, A.R. Zinsmeister and E.V. Loftus

    Version of Record online : 14 MAR 2012, DOI: 10.1002/ibd.22943

  20. You have full text access to this OnlineOpen article
    Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b

    Annals of Clinical and Translational Neurology

    Volume 2, Issue 1, January 2015, Pages: 43–55, Jens Ingwersen, Til Menge, Britta Wingerath, Derya Kaya, Jonas Graf, Tim Prozorovski, Andreas Keller, Christina Backes, Markus Beier, Matthias Scheffler, Thomas Dehmel, Bernd C. Kieseier, Hans-Peter Hartung, Patrick Küry and Orhan Aktas

    Version of Record online : 5 DEC 2014, DOI: 10.1002/acn3.152